Lacosamide Krka

Lacosamide, the active ingredient in Lacosamide Krka, is a sodium channel blocker presented as an oral tablet for oral use. It treats partial‑onset seizures and epilepsy in adults and children.

GNH USA supplies Lacosamide Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic drug that modulates neuronal excitability in seizure disorders.

- Partial‑onset seizures: reduces seizure frequency when used as adjunct therapy. - Epilepsy (refractory): provides additional seizure control in patients not fully managed by other agents. - Adjunctive therapy for focal epilepsy: enhances overall seizure management when combined with other antiepileptics.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild to moderate upset stomach. - Headache: persistent or intermittent pain. - Fatigue: increased tiredness or lack of energy. - Blurred vision: temporary visual disturbances. - Diplopia: double vision in some patients.

Serious or Rare Side Effects: - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation. - Severe rash: including Stevens‑Johnson syndrome. - Cardiac arrhythmia: especially PR‑interval prolongation. - Respiratory depression: marked slowing of breathing. - Anaphylaxis: acute allergic reaction with hives, swelling, or difficulty breathing. - Hepatotoxicity: signs of liver injury such as jaundice.

Before initiating Lacosamide, clinicians should evaluate several safety considerations.

- Renal impairment: adjust dose in patients with reduced kidney function. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiac conduction: obtain baseline ECG; avoid in patients with significant PR‑interval prolongation. - Pregnancy: use only if potential benefit justifies potential risk; data are limited. - Concomitant CNS depressants: monitor for enhanced sedation or respiratory effects. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Lacosamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels. - Strong CYP3A4 inducers (e.g., carbamazepine): may reduce efficacy. - Other sodium‑channel blockers (e.g., phenytoin): risk of additive cardiac effects.

Moderate Interactions (Monitor Closely): - Opioids: potential for enhanced CNS depression. - Alcohol: may increase dizziness and sedation. - Anticoagulants (e.g., warfarin): monitor INR for possible changes. - Antidepressants (e.g., SSRIs): watch for mood alterations. - Diuretics: may affect electrolyte balance influencing cardiac conduction.